HK$4.39
0.80%
Hong Kong, Sep 21, 04:00 pm HKT. Closed.
ISIN
HK0000311099
Symbol
3320

China Resources Pharmaceutic Target price 2026 - Analyst rating & recommendation

China Resources Pharmaceutic Classifications & Recommendation

Buy
86%
Hold
14%

China Resources Pharmaceutic Price Target

Target Price HK$6.43
Price HK$4.38
Potential
Number of Estimates 11
11 Analysts have issued a price target China Resources Pharmaceutic 2027 . The average China Resources Pharmaceutic target price is HK$6.43. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 14 analysts: 12 Analysts recommend China Resources Pharmaceutic to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the China Resources Pharmaceutic stock has an average upside potential 2027 of . Most analysts recommend the China Resources Pharmaceutic stock at Purchase.

Sales and Margin forecast 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Revenue Billion HK$ 315.67 324.27
4.62% 2.72%
EBITDA Margin 6.64% 6.32%
4.54% 4.83%
Net Margin 1.50% 1.49%
15.40% 0.71%

11 Analysts have issued a sales forecast China Resources Pharmaceutic 2026 . The average China Resources Pharmaceutic sales estimate is

HK$324b
unlock
. This is
1.75% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
HK$363b 13.78%
unlock
, the lowest is
HK$276b 13.40%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 HK$316b 4.62%
2026
HK$324b 2.72%
unlock
2027
HK$339b 4.41%
unlock
2028
HK$341b 0.66%
unlock

10 China Resources Pharmaceutic Analysts have issued a net profit forecast 2026. The average China Resources Pharmaceutic net profit estimate is

HK$4.8b
unlock
. This is
0.38% lower
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
HK$5.5b 12.73%
unlock
, the lowest is
HK$3.9b 19.94%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 HK$4.7b 20.73%
2026
HK$4.8b 2.32%
unlock
2027
HK$5.2b 7.68%
unlock
2028
HK$5.1b 1.51%
unlock

Net Margin

2025 1.50% 15.40%
2026
1.49% 0.71%
unlock
2027
1.54% 3.36%
unlock
2028
1.51% 1.95%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share HK$ 0.75 0.77
20.97% 2.67%
P/E 5.64
EV/Sales 0.22

10 Analysts have issued a China Resources Pharmaceutic forecast for earnings per share. The average China Resources Pharmaceutic EPS is

HK$0.77
unlock
. This is
0.00% lower
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
HK$0.87 12.99%
unlock
, the lowest is
HK$0.62 19.48%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 HK$0.75 20.97%
2026
HK$0.77 2.67%
unlock
2027
HK$0.83 7.79%
unlock
2028
HK$0.82 1.20%
unlock

P/E ratio

Current 5.65 41.25%
2026
5.64 0.17%
unlock
2027
5.24 7.09%
unlock
2028
5.32 1.53%
unlock

Based on analysts' sales estimates for 2026, the China Resources Pharmaceutic stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.23
2026
0.22 3.61%
unlock
2027
0.21 4.24%
unlock
2028
0.21 0.61%
unlock

P/S ratio

Current
2026
0.08 1.78%
unlock
2027
0.08 4.23%
unlock
2028
0.08 0.63%
unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today